Text size :

Healthcare: asthma and polyposis, Palcic (Sifo Fvg) ‘ultra long-acting treatments useful for patients and NHS’ (2)

ADNKRONOS

November 9, 2026

(Adnkronos Health) – The public healthcare pharmacist, in their evolution, “will not only maintain drug governance,” emphasizes the expert, “but will increasingly become a figure capable of governing the entire care pathway, across different care settings. Their role will therefore also be to promote appropriateness, adherence to therapies, and the culture of outcomes. As pharmacists, I believe we must increasingly appropriate the value of the drug, understood as the health outcomes we manage to achieve. We must not only consider traditional parameters, such as packaging and expenditure, which naturally remain important and must be monitored, but we must take a further step forward, assuming an increasingly strategic role in the governance of the entire process and care pathway.”

Innovation arrives, “but it must be made usable,” highlights Palcic. “We must transform all its potential. It’s not enough to have a Ferrari – and fortunately, we are in a field where Ferraris exist – we also need the right highways. This means building adequate care pathways and a healthcare system organization capable of promoting the use of new therapeutic opportunities and making the results we achieve measurable. Another fundamental issue,” he points out, “is precisely measuring what we do, even as pharmacists: not only how much we have spent, but also how much health we have produced. We must certainly address the issue of sustainability, which is dear to everyone because, otherwise, the system could not sustain itself. But we must also consider how much it would cost us not to adequately treat patients. There are so-called grey areas where we can intervene, eliminating inefficiencies and situations of overspending. We can free up resources through the use of certain drugs, I’m thinking of biosimilars or other therapeutic opportunities that allow for resource recovery. At the same time, however, there are areas where investment is necessary to subsequently obtain a return in terms of citizens’ health.”

Corporate organization can also make a difference. “In my reality, for example,” illustrates the expert, “the university hospital company has been integrated with the territorial company. This is a model still not very widespread in Italy, also shared with the Friuli Centrale University Health Authority in Udine. This structure favors 360-degree pharmaceutical governance. Normally, the hospital company is considered primarily a cost-generating center; in my case, however, I follow both components: both the specialist and hospital component and that of territorial pharmaceutical governance. Keeping hospital and territorial companies still separate can lead to further fragmentation and make overall governance less effective. An integrated organization,” he concludes, “instead allows for a broader and more coordinated vision of the entire care pathway.”

Jiji Press

Related

Page TOP